← Leaderboards
Arnab Ghosh
Cleveland Clinic Lerner Com-Cwru
$2,113,694
Attributed
$2,113,694
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $479.2K · FY2019–23$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,113,694 · 2
By mechanism
R01$1,700,049 · 1
R56$413,645 · 1
Top collaborators
No co-investigators on record.
Most similar at Cleveland Clinic Lerner Com-Cwru
Same institution · by research overlap
- Serpil C. Erzurum$45,061,611
- Kewal Asosingh$2,975,100
- Suzy Comhair$4,373,488
- Tyler Eugene Miller$823,129
- Anita Borton Hjelmeland$6,940,856
Others in their field
Other Emerging Leaders on “Inflammatory”
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$21,969,486
- Gary Fanger · Rise Therapeutics, Llc$20,823,569
- Gina Montealegre · Leidos Biomedical Research, Inc.$19,781,641
- Jeffrey Reich · Sparian Biosciences, Inc.$13,729,307
- Bjorn E Oskarsson · Mayo Clinic Jacksonville$11,846,278
- James Dale Berry · Brigham And Women'S Hospital$11,004,714
Research focus
InflammatoryMammalsFutureInflammationApicalLifeA549Functional DisorderHemeHeterodimerizationAsthmaticBiologyAsthmatic AirwayBronchodilationAsthmatic Airway Smooth MuscleCatalaseAsthmaEnzymesAsthma ModelClinical DiagnosisHemeproteinsHemoglobinDisease DiagnosisMolecular
Grant awards (6)
Nitric oxide induced soluble guanylate cyclase dysfunction or activation: Implications as a disease indicator or in therapy$401,900
R01 · FY2023 · HL · contact PI
Nitric oxide induced soluble guanylate cyclase dysfunction or activation: Implications as a disease indicator or in therapy$77,280
R01 · FY2023 · HL · contact PI
Nitric oxide induced soluble guanylate cyclase dysfunction or activation: Implications as a disease indicator or in therapy$401,910
R01 · FY2022 · HL · contact PI
Nitric oxide induced soluble guanylate cyclase dysfunction or activation: Implications as a disease indicator or in therapy$403,595
R01 · FY2021 · HL · contact PI
Nitric oxide induced soluble guanylate cyclase dysfunction or activation: Implications as a disease indicator or in therapy$415,364
R01 · FY2020 · HL · contact PI
Nitric oxide induced soluble guanylate cyclase dysfunction or activation: Implications as disease biomarkers or in therapy$413,645
R56 · FY2019 · HL · contact PI